Navigation Links
Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
Date:5/9/2011

BLUE BELL, Pa., May 9, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV). These results were presented at the 15th Annual Conference on Women's Health Care Issues, hosted in New York by the International Infectious Disease Society for Obstetrics and Gynecology-USA, by Mark Bagarazzi, MD, Inovio's chief medical officer.

The data were generated through a long-term assessment of participants in Inovio's Phase I study of 18 adult females with moderate or severe cervical intraepithelial neoplasia (CIN 2/3), a high-grade premalignant lesion that may lead to cervical cancer. This study was designed to assess immune responses generated by and safety of the vaccine.

In this study, 72% of vaccinated subjects (13 of 18) developed significant antigen-specific T-cell responses during the first four months of treatment (each patient was vaccinated at months 0, 1, and 3) by standardized interferon-γ ELISpot assay. The third and highest dose group displayed the strongest level of T cell responses, with 83% (5 of 6) positive responders. The level of T cell responses in positive responders ranged from 100 to over 5000 spot forming units (SFU) per million cells when measured after overnight stimulation in the standardized ELISpot assay. In contrast, competing vaccine approaches targeting HPV therapy have consistently shown sub-100 SFU levels even when using more sensitive assays.

This newly reported data evaluated 11 of 13 pos
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
2. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
3. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
4. Vanda Pharmaceuticals Reports First Quarter 2011 Results
5. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
6. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
8. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
10. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
11. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/27/2015)...   PureTech , a science and technology R&D ... and technologies in the healthcare sector, announced today the ... Member of the Board of Directors of Sanofi, to ... been a pleasure to know Chris for many years ... working together more closely now," said Dr. Robert ...
(Date:2/26/2015)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... and commercializes proprietary technologies and products for advanced microarray ... the fiscal first quarter ended December  31, 2014. All ... (CAD), unless otherwise stated. "During the ... our existing customers and add to our sales pipeline," ...
(Date:2/26/2015)... DuPont Executive Vice President James C. ... advancements and product launches across the Agriculture and Nutrition ... Lynch 2015 Global Agriculture Conference. "While ... the last two years, long-term demand for agricultural production ... last decade, when demand for corn and soybeans increased ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... Company CEO is featured speaker: "Case Study - Screening ... Safety and Efficacy" on Friday, September 26 ... feature its expanding,line of ion channel services and cell ... the Assays and Cellular Targets,conference in San Diego, September ...
... today announced the publication of its first peer-reviewed ... Experiments (JoVE).,This makes Sigma-Aldrich the first life science ... scientific publication process. Peer-reviewed,video protocols are an innovative ... scientific communication and with it the speed of ...
... 17 /PRNewswire-FirstCall/ - On August 20, 2008,Oncothyreon Inc. (Nasdaq: ... received a,letter from The Nasdaq Stock Market indicating that ... listing on The NASDAQ Global Market,because it did not ... among other things, that the market value of,its common ...
Cached Biology Technology:ChanTest to Highlight the World's Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11 2Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE 2Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE 3Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards 2Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards 3
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... had two or more induced abortions have a reduced risk ... to what degree physical activity during pregnancy protects against pre-eclampsia, ... studies from the Norwegian Institute of Public Health (NIPH) that ... (MoBa). The new results from MoBa were presented ...
... It is well known that plants growing under unfavourable conditions ... it is estimated that in the US, abiotic stress reduces ... A spectacular example of the effect of stress in ... by bonsai trees, in which every aspect of their stature, ...
... State University has made a breakthrough that could lead to ... implants. The researchers have found that the unique properties of ... that can be implanted into the human body including ... can scrub impurities from the blood. Researchers have long ...
Cached Biology News:Previous abortions and exercise: Do they affect pregnancy? 2Previous abortions and exercise: Do they affect pregnancy? 3The bonsai effect: Wounded plants make jasmonates, inhibiting cell division, stunting growth 2NC State finds new nanomaterial could be breakthrough for implantable medical devices 2
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
...
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
... Polyclonal to Human CELSR3 CELSR3 is an ... In mouse, this gene is expressed during development ... mice and rats in brain, spinal cord, dorsal ... from human B-cell/lung/testis, blood, brain, colon, heart/melanocyte/uterus, lung, ...
Biology Products: